Renaissance Technologies
LCTX icon

Renaissance Technologies’s Lineage Cell Therapeutics LCTX Stock Holding History

Renaissance Technologies’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Sell
1,344,829
-780,271
-37% -$1.08M ﹤0.01% 2036
2026
Q1 		$3.36M Sell
2,125,100
-279,700
-12% -$472K 0.01% 1599
2025
Q4 		$4.02M Buy
2,404,800
+499,167
+26% +$864K 0.01% 1433
2025
Q3 		$3.22M Sell
1,905,633
-66,702
-3% -$78.9K ﹤0.01% 1743
2025
Q2 		$1.79M Sell
1,972,335
-319,046
-14% -$189K ﹤0.01% 2179
2025
Q1 		$1.03M Buy
2,291,381
+8,309
+0.4% +$4.87K ﹤0.01% 2409
2024
Q4 		$1.15M Buy
2,283,072
+2,085,972
+1,058% +$1.53M ﹤0.01% 2422
2024
Q3 		$178K Sell
197,100
-386,522
-66% -$358K ﹤0.01% 3146
2024
Q2 		$582K Buy
583,622
+53,022
+10% +$58.6K ﹤0.01% 2625
2024
Q1 		$785K Buy
530,600
+380,600
+254% +$432K ﹤0.01% 2639
2023
Q4 		$164K Buy
150,000
+90,300
+151% +$98.9K ﹤0.01% 3193
2023
Q3 		$70K Buy
59,700
+3,800
+7% +$5.17K ﹤0.01% 3321
2023
Q2 		$79K Buy
+55,900
New +$77.2K ﹤0.01% 3520
2021
Q1 		– Sell
-23,000
Closed -$40K – 3532
2020
Q4 		$40K Sell
23,000
-437,806
-95% -$612K ﹤0.01% 3327
2020
Q3 		$432K Sell
460,806
-30,894
-6% -$27.3K ﹤0.01% 2867
2020
Q2 		$428K Buy
491,700
+223,300
+83% +$197K ﹤0.01% 2924
2020
Q1 		$222K Buy
+268,400
New +$267K ﹤0.01% 3077
2019
Q1 		– Sell
-259,300
Closed -$237K – 3587
2018
Q4 		$237K Buy
+259,300
New +$397K ﹤0.01% 3092
2018
Q3 		– Sell
-166,421
Closed -$300K – 3459
2018
Q2 		$300K Sell
166,421
-721,004
-81% -$1.45M ﹤0.01% 2960
2018
Q1 		$2.09M Sell
887,425
-481,660
-35% -$1.13M ﹤0.01% 2306
2017
Q4 		$2.58M Buy
1,369,085
+922,972
+207% +$2.02M ﹤0.01% 2190
2017
Q3 		$1.11M Buy
446,113
+302,544
+211% +$750K ﹤0.01% 2541
2017
Q2 		$396K Buy
143,569
+22,614
+19% +$63.2K ﹤0.01% 2827
2017
Q1 		$365K Buy
+120,955
New +$343K ﹤0.01% 2858
2015
Q3 		– Sell
-204,437
Closed -$599K – 3269
2015
Q2 		$599K Buy
+204,437
New +$793K ﹤0.01% 2668
2014
Q2 		– Sell
-64,057
Closed -$170K – 2876
2014
Q1 		$170K Buy
+64,057
New +$189K ﹤0.01% 2644

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies's LCTX Position: Q2 2026 in Review

Renaissance Technologies reduced its Lineage Cell Therapeutics (LCTX) stake by 37% in Q2 2026, selling an estimated $1.08M and leaving 1,344,829 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2036.

Renaissance Technologies first reported a position in LCTX in Q1 2014 and has held it in 26 quarters since. The position peaked at $4.02M in Q4 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Renaissance Technologies held 1,344,829 shares of Lineage Cell Therapeutics worth $1.76M as of Q2 2026.
  • Renaissance Technologies sold 780,271 Lineage Cell Therapeutics shares in Q2 2026, an estimated $1.08M.
  • Lineage Cell Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2036 holding.
  • Renaissance Technologies first reported a position in Lineage Cell Therapeutics in Q1 2014 and has held it in 26 quarters since.
  • Renaissance Technologies's Lineage Cell Therapeutics position peaked at $4.02M in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.